Valuation: Glaukos Corporation

Market Cap 1.4TCr 1.25TCr 1.16TCr 1.05TCr 1.99TCr 1,31000Cr 2.04TCr 14TCr 5.51TCr 70TCr 5.24TCr 5.13TCr 2,21900Cr P/E 2026 *
-798x
P/E 2027 * 180x
Enterprise Value 1.38TCr 1.24TCr 1.14TCr 1.04TCr 1.96TCr 1,29600Cr 2.02TCr 14TCr 5.45TCr 69TCr 5.19TCr 5.08TCr 2,19600Cr EV / Sales 2026 *
17.7x
EV / Sales 2027 * 13.6x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week+1.35%
Current month-0.59%
1 month+42.55%
3 months+30.19%
6 months+76.89%
Current year+109.18%
1 week 218.76
Extreme 218.765
250.4
1 month 162.97
Extreme 162.97
255.18
Current year 93.96
Extreme 93.96
255.18
1 year 87.32
Extreme 87.3196
255.18
3 years 59.22
Extreme 59.22
255.18
5 years 33.33
Extreme 33.33
255.18
10 years 23.08
Extreme 23.075
255.18
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
Director of Finance/CFO 50 05/05/2017
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Exercice

Director

7,500 0.0131%
30/10/26 Don

Director

-4,764 0.0083%
30/10/26 Exercice

Executive/Senior Manager

70,374 0.1227%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+1.35%+167.33%+290.14% 1.41TCr
-0.05%+0.97%-12.26%+17.55% 19TCr
-1.17%+2.74%+9.64%+43.73% 13TCr
-0.44%+4.42%-8.66%+18.52% 12TCr
-1.57%+1.82%-39.83%+7.26% 9.81TCr
+0.85%+2.41%-4.37%+76.50% 6.6TCr
-1.23%+7.29%+17.05%-9.39% 5.86TCr
-1.42%+3.66%-1.82%+62.49% 5.57TCr
+1.04%-2.76%-4.77%+54.06% 4.88TCr
+1.08%+3.41%+4.00%-4.71% 3.6TCr
Average -0.41%+2.12%+12.63%+55.61% 8TCr
Weighted average by Cap. -0.48%+2.47%-3.95%+32.27%

Financials

2026 *2027 *
Net sales 78Cr 70Cr 65Cr 59Cr 110.88Cr 7.32TCr 113.97Cr 772.41Cr 307.75Cr 3.92TCr 292.93Cr 286.71Cr 12TCr 100.35Cr 90Cr 83Cr 75Cr 142.55Cr 9.41TCr 146.53Cr 993.05Cr 395.66Cr 5.04TCr 376.6Cr 368.61Cr 16TCr
Net income -1.74Cr -1.56Cr -1.44Cr -1.3Cr -2.47Cr -162.81Cr -2.54Cr -17Cr -6.85Cr -87Cr -6.52Cr -6.38Cr -275.75Cr 7.63Cr 6.84Cr 6.3Cr 5.72Cr 11Cr 715Cr 11Cr 75Cr 30Cr 383.08Cr 29Cr 28Cr 1.21TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.4TCr -22Cr -147.71Cr -59Cr -749.78Cr -56Cr -55Cr -2.37TCr -30Cr -27Cr -25Cr -22Cr -42Cr -2.79TCr -43Cr -294.59Cr -117.37Cr -1.5TCr -111.72Cr -109.35Cr -4.73TCr
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
10/26/10 $236.19 -1.07% 8,47,902
09/26/09 $238.74 +6.39% 8,54,095
06/26/06 $224.41 +2.01% 12,02,866
05/26/05 $219.98 -10.83% 20,42,313
04/26/04 $246.70 +5.86% 20,81,409
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
236.19USD
Average target price
242.46USD
Spread / Average Target
+2.66%
  1. Stock Market
  2. Stocks
  3. GKOS Stock